Frequencies of marker chromosomes by cytogenetic entities
| . | No. of patients . | Marker positivity (%) . | P value* . |
|---|---|---|---|
| All | 1026 | 165/1026 (16.1) | |
| Cytogenetics | |||
| Adverse risk (MRC) | 558 | 148/558 (26.5) | <.001 |
| Complex aberrant (≥4) | 352 | 142/352 (40.3) | <.001 |
| Monosomal | 249 | 125/249 (50.2) | <.001 |
| Abnl(17p) | 131 | 54/131 (41.2) | <.001 |
| Abnl(5q) | 226 | 98/226 (43.4) | <.001 |
| Abnl(7q) | 243 | 80/243 (32.9) | <.001 |
| Abnl(3q) | 53 | 5/53 (9.4) | .93 |
| t(6;9)(p23;q34) | 23 | 1/23 (4.3) | .82 |
| t(9;11)(p22;q23) | 47 | 2/47 (4.3) | .21 |
| t(11;19)(q23;p13) | 12 | 0/12 (0) | .93 |
| t(v;11)(v;q23) | 47 | 0/47 (0) | .04 |
| Subclone formation | 342 | 115/342 (33.6) | <.001 |
| Derivate chromosome | 198 | 49/198 (24.7) | .006 |
| Molecular genetics | |||
| NPM1 mutation | 104 | 4/104 (3.8) | .003 |
| FLT3-ITD mutation | 128 | 4/128 (3.1) | <.001 |
| . | No. of patients . | Marker positivity (%) . | P value* . |
|---|---|---|---|
| All | 1026 | 165/1026 (16.1) | |
| Cytogenetics | |||
| Adverse risk (MRC) | 558 | 148/558 (26.5) | <.001 |
| Complex aberrant (≥4) | 352 | 142/352 (40.3) | <.001 |
| Monosomal | 249 | 125/249 (50.2) | <.001 |
| Abnl(17p) | 131 | 54/131 (41.2) | <.001 |
| Abnl(5q) | 226 | 98/226 (43.4) | <.001 |
| Abnl(7q) | 243 | 80/243 (32.9) | <.001 |
| Abnl(3q) | 53 | 5/53 (9.4) | .93 |
| t(6;9)(p23;q34) | 23 | 1/23 (4.3) | .82 |
| t(9;11)(p22;q23) | 47 | 2/47 (4.3) | .21 |
| t(11;19)(q23;p13) | 12 | 0/12 (0) | .93 |
| t(v;11)(v;q23) | 47 | 0/47 (0) | .04 |
| Subclone formation | 342 | 115/342 (33.6) | <.001 |
| Derivate chromosome | 198 | 49/198 (24.7) | .006 |
| Molecular genetics | |||
| NPM1 mutation | 104 | 4/104 (3.8) | .003 |
| FLT3-ITD mutation | 128 | 4/128 (3.1) | <.001 |
Adjusted for multiple testing.